My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 532331 | NSE: AJANTPHARM | Pharmaceuticals & Drugs | Small Cap
1. Is Ajanta Pharma Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Ajanta Pharma Ltd is a good quality company.
2. Is Ajanta Pharma Ltd undervalued or overvalued?
The key valuation ratios of Ajanta Pharma Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Ajanta Pharma Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Ajanta Pharma Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | |||
| ROCE % ⓘ | 38.3% | 38.6% | 38.3% | 36.6% | 25.5% | 17.9% | 17.7% | 23.3% | 21.7% | 16.6% | - | ||
| Value Creation Index ⓘ | 1.7 | 1.8 | 1.8 | 1.7 | 0.9 | 0.3 | 0.3 | 0.7 | 0.6 | 0.2 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 1,208 | 1,474 | 1,734 | 1,983 | 2,126 | 2,055 | 2,588 | 2,890 | 3,341 | 3,743 | 3,903 | ||
| YoY Gr. Rt. % | - | 22% | 17.7% | 14.4% | 7.2% | -3.3% | 25.9% | 11.7% | 15.6% | 12% | - | ||
| Adj EPS ⓘ | 17.6 | 23.7 | 31.2 | 39.3 | 34.9 | 29.6 | 32.7 | 50.3 | 52.6 | 43.6 | 52.4 | ||
| YoY Gr. Rt. % | - | 34.5% | 31.7% | 26% | -11.1% | -15.3% | 10.7% | 53.5% | 4.7% | -17.1% | - | ||
| BVPS (₹) ⓘ | 45 | 63.7 | 90.2 | 118.6 | 154.5 | 171.5 | 198.5 | 230.8 | 254.8 | 269.1 | 276.5 | ||
| Adj Net Profit ⓘ | 232 | 312 | 415 | 518 | 461 | 387 | 428 | 652 | 674 | 549 | 660 | ||
| Cash Flow from Ops. ⓘ | 212 | 279 | 326 | 609 | 281 | 375 | 457 | 576 | 562 | 792 | - | ||
| Debt/CF from Ops. ⓘ | 0.6 | 0.3 | 0.3 | 0 | 0 | 0.1 | 0.1 | 0 | 0 | 0 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 13.4% | 12% | 13.1% | 12% | ||||||||
| Adj EPS ⓘ | 10.6% | 4.5% | 10% | -17.1% | ||||||||
| BVPSⓘ | 22% | 11.7% | 10.7% | 5.6% | ||||||||
| Share Price | 22.4% | 20.5% | 24.5% | 60.7% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | Mar'23 | TTM | ||
| Return on Equity % ⓘ | 47 | 43.5 | 40.8 | 37.6 | 25.5 | 18.1 | 17.7 | 23.3 | 21.5 | 16.5 | 19.2 | |
| Op. Profit Mgn % ⓘ | 30.5 | 34.3 | 34.3 | 35.5 | 31 | 27.6 | 27 | 34.6 | 27.9 | 21.7 | 23.4 | |
| Net Profit Mgn % ⓘ | 19.2 | 21.2 | 23.9 | 26.1 | 21.7 | 18.8 | 16.6 | 22.6 | 20.2 | 14.7 | 16.9 | |
| Debt to Equity ⓘ | 0.2 | 0.1 | 0.1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Working Cap Days ⓘ | 125 | 116 | 121 | 120 | 143 | 206 | 210 | 233 | 228 | 207 | 224 | |
| Cash Conv. Cycle ⓘ | 39 | 49 | 62 | 51 | 58 | 88 | 93 | 104 | 122 | 125 | 154 | |
Sales growth is growing at healthy rate in last 3 years 13.09%
Net Profit is growing at healthy rate in last 3 years 10.01%
Return on Equity has declined versus last 3 years average to 19.20%
Sales growth is not so good in last 4 quarters at 8.58%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 52.9 | 52.4 |
| TTM Sales (₹ Cr.) | 3,684 | 3,903 |
| BVPS (₹.) ⓘ | 266.5 | 276.5 |
| Reserves (₹ Cr.) ⓘ | 3,331 | 3,457 |
| P/BV ⓘ | 7.31 | 7.05 |
| PE ⓘ | 36.86 | 37.16 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 1136.80 / 1980.00 |
| All Time Low / High (₹) | 1.88 / 1980.00 |
| Market Cap (₹ Cr.) | 24,533 |
| Equity (₹ Cr.) | 25.2 |
| Face Value (₹) | 2 |
| Industry PE ⓘ | 43.9 |
| Pledged * | 14.95 | 13.73 | 15.37 | 16.60 | 20.09 | 17.42 | 19.87 | 11.41 | 13.23 | 12.43 |
Ajanta Pharma is established in 1973. Committed to 'Serve Health Care Needs Worldwide', the company produces a comprehensive range of specialty products targeting different therapeutic segments for treatment of patients, customised to each market it is present in. The company's Institutional business comprises of India Business and Africa Business. In India, company is a reliable supplier for various government bodies like Armed forces, government hospitals, canteens, stores department, etc. The product basket for India market includes multivitamins, antibiotics, eye drops, cough syrups, etc. In Africa, the company was the first Generic Company to obtain 'WHO Pre-Qualification' for Anti-Malarial product, a combination of Artemether plus Lumefantrine. It has been innovating on this product since then and has given many new variations for patient convenience and compliance.
As a part of the company’s philosophy to build sustainable and scalable business model, it set its eye on entering the world’s largest and most stringent pharmaceutical market-USA. It carved out select product portfolio which include complex technology products to get the competitive advantage in the market place. It has also made substantial investments in its R&D facilities and thereby acquired required technical and regulatory expertise to penetrate the market. It has an advanced Research & Development Centre for finished formulations and Active Pharmaceutical Ingredient (API) synthesis of different dosage forms.
Business area of the company
Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages. Its business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. Emerging markets are the major contributors in company’s branded generic business where it is present across Asia and Africa. It has designed customised basket of products for each of these markets and serve wide range of therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products.
Awards and accreditations
Major events and milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Download APP
